Helius Medical Technologies(HSDT)

Search documents
Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024
Newsfilter· 2024-05-10 13:00
NEWTOWN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its first quarter 2024 financial results on Monday, May 13, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference cal ...
Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering
Newsfilter· 2024-05-07 02:15
NEWTOWN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the pricing of a public offering of 804,999 shares of its Class A common stock ("Common Stock") and 2,047,222 Pre-Funded Warrants, each to purchase one share of Common Stock, together with accompanying Series A and Series B warrants to purchase up to an ...
Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center
Newsfilter· 2024-04-24 13:05
-- Helius Medical and Shepherd Center partner on a study that aims at rehabilitating walking mobility in people recovering from stroke ---- Shepherd Center, a top neurorehabilitation hospital, is the third site in Helius' U.S. registrational program for Portable Neuromodulation Stimulator (PoNS®) in stroke ---- The single-arm study will evaluate PoNS in treating gait and balance deficits in chronic stroke survivors ---- Regulatory submission seeking marketing authorization for stroke expected in 2025-- NEWT ...
Helius Medical Technologies(HSDT) - 2023 Q4 - Annual Report
2024-03-28 20:30
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the Fiscal Year Ended December 31, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from _____ to _____ Commission File No. 001-38445 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 36-4787690 ...
Helius Medical Technologies(HSDT) - 2023 Q4 - Annual Results
2024-03-28 20:15
Exhibit 99.1 Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results -- Company to host call at 4:30pm today – NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December 31, 2023. Fourth Quarter and Recent Business Updat ...
Helius Medical Technologies(HSDT) - 2023 Q3 - Quarterly Report
2023-11-09 21:30
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as specified in its charter) | Delaware | 36-4787690 | ...
Helius Medical Technologies(HSDT) - 2023 Q2 - Quarterly Report
2023-08-10 20:30
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as specified in its charter) | Delaware | 36-4787690 | | -- ...
Helius Medical Technologies(HSDT) - 2023 Q1 - Quarterly Report
2023-05-11 20:20
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from to Commission File No. 001-38445 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as specified in its charter) | Delaware | 36-4787690 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | 642 Newtown Yardley Road, Suite 100 | 18940 | | Newtown, Pennsylvania | | | (Address of principal executive offices ...
Helius Medical Technologies(HSDT) - 2022 Q4 - Earnings Call Transcript
2023-03-10 23:19
Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Michelle Bilski - In-Site Communications Dane Andreeff - President & Chief Executive Officer Jeffrey Mathiesen - Chief Financial Officer Antonella Favit-Van Pelt - Chief Medical Officer Conference Call Participants Jonathan Aschoff - ROTH MKM Partners Destiny Hance - Ladenburg Thalmann Anthony Vendetti - Maxim Group Operator Good day, and thank you for standing by. Welcome to the H ...
Helius Medical Technologies(HSDT) - 2022 Q4 - Annual Report
2023-03-09 21:39
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the Fiscal Year Ended December 31, 2022 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from _____ to _____ Commission File No. 001-38445 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 36-4787690 ...